Literature DB >> 20437121

High frequency of MEFV gene mutations in patients with myeloid neoplasm.

Cagatay Oktenli1, Ozkan Sayan, Serkan Celik, Alev A Erikci, Yusuf Tunca, Hakan M Terekeci, Elcin Erkuvan Umur, Yavuz S Sanisoglu, Deniz Torun, Fatih Tangi, Burak Sahan, Selim Nalbant.   

Abstract

We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms. The frequency of the five most common MEFV gene mutations (M694V, M680I, V726A, E148Q and M694I) was determined in 26 patients with myeloid neoplasm. We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever. The mean overall mutation rate was 0.269. We found a high frequency of carriers in patients with myelodysplastic syndrome (66.6%), polycythemia vera (33.3%) and acute myeloid leukemia (28.6%). However, there was no MEFV gene mutation in patients with chronic myeloid leukemia. In conclusion, this study reports for the first time a possibly high prevalence of MEFV gene mutations in patients with myeloid neoplasm, especially myelodysplastic syndrome, polycythemia vera and acute myeloid leukemia. Our findings could open new perspectives for MEFV gene mutations in myeloid neoplasms and its association with tumor promotion. Further research is needed to determine the actual role of MEFV gene mutations in these malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437121     DOI: 10.1007/s12185-010-0577-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  41 in total

1.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 2.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Authors:  Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

3.  Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis.

Authors:  Jae Jin Chae; Hirsh D Komarow; Jun Cheng; Geryl Wood; Nina Raben; P Paul Liu; Daniel L Kastner
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

4.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

5.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  A very frequent mutation and remarkable association of R761H with M694V mutations in Turkish familial Mediterranean fever patients.

Authors:  Erkan Demirkaya; Yusuf Tunca; Faysal Gok; Seza Ozen; Davut Gul
Journal:  Clin Rheumatol       Date:  2007-11-14       Impact factor: 2.980

7.  Familial Mediterranean fever attacks do not alter functional and morphologic tissue Doppler echocardiographic parameters.

Authors:  Hakan M Terekeci; Eralp R Ulusoy; Nezihi M Kucukarslan; Selim Nalbant; Cagatay Oktenli
Journal:  Rheumatol Int       Date:  2008-07-23       Impact factor: 2.631

8.  The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation.

Authors:  Christian Stehlik; Maryla Krajewska; Kate Welsh; Stanislaw Krajewski; Adam Godzik; John C Reed
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

9.  Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome.

Authors:  Ko Sasaki; Toshiyuki Tahara; Kinuko Mitani
Journal:  Int J Hematol       Date:  2009-05-23       Impact factor: 2.490

10.  Does immune activation continue during an attack-free period in familial Mediterranean fever?

Authors:  U Musabak; A Sengul; C Oktenli; S Pay; Z Yesilova; L Kenar; S Y Sanisoglu; A Inal; A Tuzun; A Erdil; S Bagci
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

View more
  5 in total

Review 1.  High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility?

Authors:  Cagatay Oktenli; Serkan Celik
Journal:  Int J Hematol       Date:  2012-03-28       Impact factor: 2.490

2.  Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Serkan Celik; Cagatay Oktenli; Emrah Kilicaslan; Fatih Tangi; Ozkan Sayan; H Onur Ozari; Osman Ipcioglu; Yavuz S Sanisoglu; M Hakan Terekeci; Alev A Erikci
Journal:  Int J Hematol       Date:  2012-02-18       Impact factor: 2.490

3.  High Frequency of Inherited Variants in the MEFV Gene in Acute Lymphocytic Leukemia.

Authors:  Ozkan Sayan; Emrah Kilicaslan; Serkan Celik; Fatih Tangi; Alev A Erikci; Osman Ipcioglu; Yavuz S Sanisoglu; Selim Nalbant; Cagatay Oktenli
Journal:  Indian J Hematol Blood Transfus       Date:  2011-07-21       Impact factor: 0.900

4.  [Multiple myeloma occurring in a familial Mediterranean fever].

Authors:  Bouomrani Salem; Farah Afef; Bouassida Nadia; Ayadi Nabil; Bahloul Zouhir; Béji Maher
Journal:  Pan Afr Med J       Date:  2013-08-07

5.  Increased frequency of Mediterranean fever gene variants in multiple myeloma.

Authors:  Serkan Celik; Fatih Tangi; Cagatay Oktenli
Journal:  Oncol Lett       Date:  2014-08-04       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.